KEEP Summary Figures S32. Am J Kidney Dis. 2011;57(3)(suppl 2):S32-S56
|
|
- Kenneth Chase
- 5 years ago
- Views:
Transcription
1 21 Summary Figures S32
2 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated blood glucose (WHO); fasting blood sugar 126 mg/dl or nonfasting blood sugar 2 mg/dl, or A1c 7% (if available) SELF-REPORTED DIABETES Self-reported diabetes or self-reported diabetic retinopathy GLYCEMIC CONTROL Fasting blood sugar <126 mg/dl or non-fasting blood sugar <2 mg/dl, and A1c <7% (if available) HYPERTENSION Self reported history hypertension, receiving a medication for hypertension, or elevated blood pressure (JNC7): Diabetes or ; systolic 13 mmhg or diastolic 8 mmhg, otherwise systolic 14 mmhg or diastolic 9 mmhg SELF-REPORTED HYPERTENSION Self-reported hypertension BLOOD PRESSURE CONTROL Diabetes or : systolic <13 mmhg and diastolic <8 mmhg, otherwise systolic <14 mmhg and diastolic <9 mmhg HIGH CHOLESTEROL Self-reported high cholesterol or receiving medication for cholesterol, or cholesterol level >2 mg/dl SELF-REPORTED HIGH CHOLESTEROL Self-reported high cholesterol CHOLESTEROL CONTROL Total cholesterol levels of 2 mg/dl SELF-REPORTED CARDIOVASCULAR DISEASE Participant reports any of the following cardiac events: heart attack, bypass surgery, heart angioplasty, stroke, heart failure, abnormal heart rhythm, or PVD (only for version 2) MICROALBUMINURIA Albumin/creatinine ratio 3 mg/g CHRONIC KIDNEY DISEASE egfr <6 ml/min/1.73 m 2 or egfr 6 ml/min/1.73 m 2 and albumin-creatinine ratio (ACR) 3 mg/g. GFR estimated using the IDMS-traceable 4-variable Modification of Diet in Renal Disease (MDRD) Study equation or Chronic Kidney Disease Epidemiology Collaboration equation (-EPI) for calibrated serum creatinine (Scr) values STAGES Stage 1: egfr 9 ml/min/1.73 m 2, and ACR 3 mg/g Stage 2: egfr 6 89 ml/min/1.73 m 2, and ACR 3 mg/g Stage 3: egfr 3 59 ml/min/1.73 m 2 Stage 4: egfr ml/min/1.73 m 2 Stage 5: egfr <15 ml/min/1.73 m 2 ANEMIA WHO Male: hemoglobin <13 g/dl Female: <12g/dl KDOQI (26) Males: hemoglobin <13.5 g/dl Women <12g/dl BODY MASS INDEX CATEGORIES UW: underweight, BMI <18.5 N: normal, BMI OW: overweight, BMI OB: obese, BMI EOB: extremely obese, BMI 4 EDUCATIONAL STATUS GSL: Grade school or less SHS: Some high school HSG: High school graduate SC+: Some college, college graduate, post-graduate DATA ANALYSES SELF-REPORTED DIABETES To be classified as having self-reported diabetes, participants had to report being told by a doctor, at any time, that they had diabetes or sugar diabetes other than that related to pregnancy. Participants answering borderline to the question were classified as non-diabetic. SELF-REPORTED HYPERTENSION Self-reported hypertension was identified by an affirmative answer to the question: Have you ever been told by a doctor that you had hypertension, also called high blood pressure. SELF-REPORTED HIGH CHOLESTEROL Self-reported high cholesterol was identified by an affirmative answere to the question: Have you ever been told by a doctor or other health professional that your blood cholesterol level was high? SELF-REPORTED CARDIOVASCULAR DISEASE Participant reports any of the following cardiac events: coronary heart disease, angina/angina pectoris, heart attack, congestive heart failure, or stroke. MICROALBUMINURIA Albumin/creatinine ratio 3 mg/g CHRONIC KIDNEY DISEASE egfr <6 ml/min/1.73 m 2 or egfr 6 ml/min/1.73 m 2 and albumin-creatinine ratio (ACR) 3 mg/g. GFR estimated using the IDMS-traceable 4-variable Modification of Diet in Renal Disease (MDRD) Study equation or Chronic Kidney Disease Epidemiology Collaboration equation (-EPI) for calibrated serum creatinine (Scr) values STAGES Stage 1: egfr 9 ml/min/1.73 m 2, and ACR 3 mg/g Stage 2: egfr 6 89 ml/min/1.73 m 2, and ACR 3 mg/g Stage 3: egfr 3 59 ml/min/1.73 m 2 Stage 4: egfr ml/min/1.73 m 2 Stage 5: egfr <15 ml/min/1.73 m 2 ANEMIA WHO Male: hemoglobin <13 g/dl Female: <12g/dl KDOQI (26) Males: hemoglobin <13.5 g/dl Women <12g/dl BODY MASS INDEX CATEGORIES UW: underweight, BMI <18.5 N: normal, BMI OW: overweight, BMI OB: obese, BMI EOB: extremely obese, BMI 4 EDUCATIONAL STATUS GSL: Grade school or less HSG: High school graduate SC+: Some college, college graduate, post graduate S33
3 Program accessibility s.1 cumulative # of partic. (in 1,s) 1 124, Cumulative # of affiliates Cumulative number of eligible participants & affiliates, by year (2 29), N = 124,9 s.2 Geographic variations in the percent of participants, by state (2 29), N = 124,9 participants (%) (4.9) 1.97 to < to < to <1.3 Below.32 (.12) South Carolina Florida Indiana East Tennessee Mass./Rhode Isl./N. Hampshire/Vermont Virginia Utah Greater New York The Alleghenies Louisiana Kentucky Connecticut Georgia National Capital Area North Carolina Arizona Hawaii North Texas Ohio Minnesota/Dakotas Percent of participants s.3 Twenty largest affiliates, by percentage of participants screened (rank order) (2 29), N = 124,9 S34
4 Program accessibility s.a Total eligible participants, by year (2 29), N = 124, All All (%) ,4 1,85 1,391 1, ,77 1,19 9, ,491 1,977 2,393 2,939 3,984 3,685 2,87 3,5 2,698 25, ,97 2,651 3,422 4,69 6,438 6,592 5,9 6,113 5,949 43, ,2 2,29 2,382 3,328 4,769 5,111 4,968 5,562 5,574 35, > ,76 1,547 1,656 1,683 1,938 1,959 11, Missing Gender Male 1,959 2,57 2,944 4,142 5,879 5,684 5,27 5,85 5,547 39, Female 4,123 5,473 6,976 8,975 12,192 12,613 1,88 11,89 11,6 84,7 68. Missing Race White 2,284 3,14 4,31 5,793 9,28 9,8 8,131 9,261 8,738 59, Black 2,652 3,392 3,43 4,274 5,267 5,565 5,41 5,42 5,479 4, Other 967 1,358 1,851 2,969 3,414 2,942 2,332 2,6 2,91 21, Unknown/missing , Ethnicity Hispanic ,117 1,89 2,416 2,317 2,75 2,164 2,317 15, Non-Hispanic 5,464 7,332 8,85 11,228 15,713 15,984 13,944 15,531 14,882 18, Education Level 6 years ,51 1, , <12 years ,188 1,779 1,763 1,581 1,57 1,492 11, years 1,585 2,192 2,591 3,491 4,611 4,462 4,19 4,531 4,527 32, >12 years 1,629 2,155 2,775 3,459 4,675 4,351 3,815 4,4 4,272 31, years 1,143 1,463 1,913 2,53 3,614 3,814 3,228 3,683 3,738 25, >16 years ,132 1,467 2,145 2,453 2,19 2,299 2,117 15, Missing ,8 1.5 Health Insurance Status Yes 4,948 6,428 7,892 1,153 14,56 14,27 12,44 13,632 12,579 96, No 883 1,234 1,66 2,49 3,251 3,371 3,292 3,525 3,88 23, Missing , All 6,82 8,44 9,922 13,118 18,129 18,31 16,19 17,695 17, ,9. "." Zero values in this cell S35
5 Targeting high-risk populations % with self-reported diabetes All s.4 Self-reported diabetes in & participants (2 29), N= 12,883 ( ), N= 22,66 s.5 participants with diabetes Percent with diabetes (2 29), N= 124,484 All Percent aware s.6 participants with diabetes who are aware of their condition (2 29), N= 38,384 All Percent treated s.7 participants with diabetes who receive medication for their condition (2 29), N= 38,384 All S36
6 Targeting high-risk populations Percent with glycemic control All s.8 Glycemic control in participants with diabetes (2 29), N= 38,384 Percent with glycemic control All s.9 Glycemic control in participants with diabetes who are being treated for their condition (2 29), N= 17,227 Percent with glycemic control All s.1 Glycemic control in participants with diabetes who are not being treated for their condition (2 29), N= 21,157 S37
7 Targeting high-risk populations % with self-reported hypertension All s.11 Self-reported hypertension in & participants (2 29), N= 12,143 ( ), N= 22,366 s.12 participants with hypertension Percent with hypertension (2 29), N= 124,492 All Percent aware s.13 participants with hypertension who are aware of their condition (2 29), N= 87,198 All Percent treated s.14 participants with hypertension who receive medication for their condition (2 29), N= 87,198 All S38
8 Targeting high-risk populations Percent controlled s.15 Blood pressure control in participants with hypertension (2 29), N= 87,198 All Percent controlled s.16 Blood pressure control in participants with hypertension who are being treated for their condition (2 29), N= 53,795 All Percent controlled s.17 Blood pressure control in participants with hypertension not being treated for their condition (2 29), N= 33,43 All S39
9 Targeting high-risk populations % with self-reported high chol : age 2-3 All s.18 Self-reported high cholesterol in & participants (2 29), N= 55,431 ( ), N= 13,535. Percent with high cholesterol All s.19 participants with high cholesterol (2 29), N= 8,186. Percent aware s.2 participants with high cholesterol who are aware of their condition (2 29), N= 49,1. All Percent treated s.21 participants with high cholesterol who receive medication for their condition (2 29), N= 49,1. All S4
10 Targeting high-risk populations Percent controlled s.22 Cholesterol control in participants with high cholesterol (2 29), N= 49,1. All Percent controlled s.23 Cholesterol control in participants with high cholesterol who are being treated for their condition (2 29), N= 14,828 All Percent controlled s.24 Cholesterol control in participants with high cholesterol who are not being treated for their condition (2 29), N= 34,322 All S41
11 Targeting high-risk populations s.25 % with self-reported CVD Gender Race/ethnicity Self-reported cardiovascular disease in participants (2 29), N= 121,543 All s.26 Percent distribution of & participants, by BMI OW: 33.2 N: 21.5 UW:.9 EO: 8.8 OW: 33.6 N: 32.8 UW: 1.9 EOB: 5.1 (2 29), N= 122,962 ( ), N= 2,567 OB: 35.6 OB: 26.5 S42
12 Prevalence of : MDRD 75 s.27 Prevalence of in & participants (2 29), N= 19,251 ( ), N= 19,553 Percent with -EPI All Percent with microalbuminuria All s.28 Prevalence of microalbuminuria in & participants (2 29), N= 111,73 ( ), N= 2,573. S43
13 Prevalence of s.b Total eligible participants with, by stage: MDRD equation (2 29), N= 124,9 Stage 1 & Stage 2 & Non- Abnormal ACR Abnormal ACR Stage 3 Stages 4-5 Missing All , ,4 9, , , ,547 25, ,81 1,272 1,815 4, ,896 43, , ,915 8, ,168 35,225 >75 4, , ,747 Gender Male 26, ,893 5, ,7 39,737 Female 55,535 2,295 3,621 13, ,276 84,7 Missing Race White 38, ,566 12, ,579 59,648 Black 27,344 1,466 1,876 4, ,442 4,2 Other 15, ,19 2, ,959 21,393 Unknown/missing ,875 2,966 Ethnicity Hispanic 1, , ,461 15,626 Non-Hispanic 71,273 2,715 4,927 17,566 1,8 11,394 18,883 U.S. Census Region Northeast 19, ,316 4, ,981 28,87 Midwest 11, , ,97 18,157 South 39,44 1,597 2,69 8, ,325 59,948 West 11, , ,631 17,498 Missing U.S. Census Division New England 6, , ,644 1,688 Middle Atlantic 12, , ,337 18,182 East North Central 7, , ,277 West North Central 4, , ,88 South Atlantic 19, ,31 4, ,221 3,911 East South Central 1, , ,339 15,983 West South Central 8, , ,765 13,54 Mountain 6, , ,656 Pacific 4, ,842 Missing Smoking Yes 3,846 1,361 2,358 7, ,444 48,231 No 48,281 1,759 2,971 1, ,551 71,564 Missing 2, ,714 Education Level 6 years 3, , ,784 <12 years 7, , ,474 11, years 2, ,511 5, , 32,18 >12 years 21, ,345 4, ,557 31, years 17, , 3, ,556 25,126 >16 years 1, , ,489 15,182 Missing 1, ,8 Health Insurance Status Yes 62,37 2,176 4,268 16, ,517 96,299 No 16, ,45 1, ,657 23,586 Missing 2, ,617 Doctor Status Yes 69,82 2,68 4,91 17,581 1,12 11,481 17,475 No 1, ,92 14,431 Missing 1, ,63 All 81,952 3,252 5,514 18,846 1,9 13, ,9 "." Zero values in this cell S44
14 Prevalence of MDRD s.29 Prevalence of in & participants, by stage (2 29), N= 11,342 ( ), N= 19,553 1 Percent with -EPI All Stage 1 Stage 2 Stage 3 Stages 4-5 s.3 MDRD 8 6 Prevalence of in & participants, by risk factor (2 29), N= 19,765 ( ), N= 19,354 Percent with EPI All No /DM /HTN /DM/HTN /Other S45
15 Prevalence of s.c Total eligible participants with, by stage: -EPI equation (2 29), N= 124,9 Stage 1 & Stage 2 & Non- Abnormal ACR Abnormal ACR Stage 3 Stages 4-5 Missing All , ,49 9, ,78 1, ,622 25, ,18 1,645 1,615 2, ,27 43, , ,918 7, ,2 35,225 >75 4, , ,747 Gender Male 26,856 1,18 1,725 4, ,546 39,737 Female 57,532 3,9 3,156 1, ,491 84,7 Missing Race White 4,452 1,36 2,3 1, ,767 59,648 Black 27,467 1,752 1,616 3, ,443 4,2 Other 15,548 1, , ,24 21,393 Unknown/missing ,875 2,966 Ethnicity Hispanic 1, , 15,626 Non-Hispanic 73,433 3,5 4,386 14,868 1,82 11,69 18,883 U.S. Census Region Northeast 19, ,18 3, ,47 28,87 Midwest 12, , ,918 18,157 South 4,482 2,36 2,289 7, ,461 59,948 West 11, , ,672 17,498 Missing U.S. Census Division New England 6, , ,686 1,688 Middle Atlantic 12, , ,361 18,182 East North Central 7, , ,277 West North Central 4, , ,88 South Atlantic 2, ,143 3, ,38 3,911 East South Central 11, , ,352 15,983 West South Central 8, , ,81 13,54 Mountain 7, , ,656 Pacific 4, ,842 Missing Smoking Yes 31,771 1,742 2,96 6, ,5 48,231 No 49,717 2,291 2,613 8, ,695 71,564 Missing 2, ,714 Education Level 6 years 4, , ,784 <12 years 7, , ,492 11, years 21,4 1,18 1,387 4, ,567 32,18 >12 years 21,831 1,117 1,165 3, ,68 31, years 18, , ,622 25,126 >16 years 1, , ,526 15,182 Missing 1, ,8 Health Insurance Status Yes 64,292 2,88 3,846 13, ,72 96,299 No 17,288 1, , ,698 23,586 Missing 2, ,617 Doctor Status Yes 71,966 3,461 4,37 14,887 1,85 11,76 17,475 No 1, ,924 14,431 Missing 1, ,63 All 84,388 4,189 4,881 15,782 1,16 14,19 124,9 "." Zero values in this cell S46
16 as a disease multiplier MDRD:, No s.31 Self-reported diabetes in & participants with or without (2 29), N= 18,755 ( ), N= 19, Percent with self-reported diabetes * -EPI: No * All anic S47
17 as a disease multiplier MDRD:, No s.32 Self-reported hypertension in & participants with or without (2 29), N= 18,755 ( ),N= 19, Percent with self-reported hypertension EPI: No All anic S48
18 as a disease multiplier MDRD:, No s.33 Self-reported high cholesterol in & participants with or without (2 29), N= 52,644 (2 29), N= 11,781 Percent with self-reported high cholesterol : 37.2 age 2-3 -EPI: No : age All anic S49
19 as a disease multiplier MDRD: No Gender Race/ethnicity s.34 Self-reported cardiovascular disease in KEEp participants with or without (2 29), N= 19, % with self-reported CVD 1 -EPI No 1 All MDRD:, No Gender s.35 BMI 3 kg/m 2 in & participants with or without (2 29), N= 19,14 ( ), N=19, Percent with BMI 3kg/m EPI: No All Male Female S
20 as a disease multiplier Percent of participants with anemia MDRD: WHO anemia EPI 3 2 KDOQI anemia s.36 Anemia (WHO & KDOQI definitions) in & participants with or without (2 29), N= 18,967 ( ), N= 19, All No All No MDRD: WHO anemia 8 Male 6 Female s.37 Anemia (WHO & KDOQI definitions) in & participants, by stage & gender KDOQI anemia * (2 29), N= 18,967 ( ), N= 19, Percent of participants with anemia EPI : WHO anemia Male Female KODQI anemia * * All Stage 1 Stage 3 No Stage 2 Stages 4-5 All * Stage 1 Stage 3 No Stage 2 Stages 4-5 S51
21 as a disease multiplier s.d Odds ratio (OR) of, by risk factor (2 29), N= 49,662 MDRD equation OR Low Upper P-value < < <.1 Male Race White 1. Black <.1 Other Hispanic <.1 Self-reported diabetes <.1 Self-reported hypertension <.1 Self-reported high cholesterol Cardiovascular disease <.1 BMI 3 kg/m <.1 Anemia (WHO definition) <.1 Insurance EPI equation OR Low Upper P-value < <.1 Male Race White 1. Black <.1 Other Hispanic <.1 Self-reported diabetes <.1 Self-reported hypertension <.1 Self-reported high cholesterol Cardiovascular disease <.1 BMI 3 kg/m <.1 Anemia (WHO definition) <.1 Insurance S52
22 Education & insurance HSG: 26.2 SHS: 9.6 GSL: 5.5 HSG: 26.1 GSL: 2.7 s.38 Percent distribution of & participants, by educational status (2 29), N= 122,658 ( ), N= 22,553 SC SC+: 53.2 Percent with insurance Gender s.39 Insurance coverage in & participants, by age & gender (2 29), N= 124,43 ( ), N= 22,3 All Male Female Non- Medicare: 39 Mcare with other than Mcaid: 11.9 Medicare 11.4 Unknown or missing: 34.5 Mcare/Mcaid: 3.3 s.4 Percent distribution of types of insurance in participants reporting they have insurance (2 29), N= 124,9 Percent with insurance s.41 Insurance coverage in & participants, by race & ethnicity (2 29), N= 1 21,536 race, N= 124,2 ethnicity ( ), N= 22,3 White Black Other Hispanic S53
23 RRT & mortality outcomes s.e Hazard ratio of RRT, controlled by risk factors (2 29), N= 96,39 s.f Hazard ratio of death, controlled by risk factors (2 29), N= 11,417 Estimate SE P-value Hazard ratio <.1.41 Male < Race White 1. Black Other Hispanic Self-reported diabetes Self-reported hypertension Cardiovascular disease BMI 3 kg/m Anemia (WHO definition) < Insurance egfr(continuous) -.9. <.1.91 ACR>=3mg/g < MDRD Study Equation Estimate SE P-value Hazard ratio < < < Male.49.4 < Race White 1. Black Other Hispanic Self-reported diabetes.41.4 <.1 1. Self-reported hypertension Cardiovascular disease.49.4 < BMI 3 kg/m Anemia (WHO definition).61.5 < Insurance by MDRD non- 1. stage < stage < stage < EPI Equation Estimate SE P-value Hazard ratio < < < Male.48.4 < Race White 1. Black Other Hispanic Self-reported diabetes.4.4 <.1 1. Self-reported hypertension Cardiovascular disease.49.4 < BMI 3 kg/m Anemia (WHO definition).59.5 < Insurance by -EPI non- 1. stage < stage < stage <.1 2. S54
24 RRT & mortality outcomes Rate per 1, patient years All s.42 Rates of renal replacement therapy (RRT) in participants, by age, gender, race & ethnicity (2 29), N= 14,822 Rate per 1, patient years MDRD equation Stage 1 Stage 2 Stage 3-5 -EPI equation Stage 1 Stage 2 Stages 3-5 Rate per 1, patient years All s.43 Mortality rates in participants, by age, gender, & race & ethnicity (2 29), N= 19,83 Rate per 1, patient years MDRD equation Stage 1 Stage 2 Stages 3-5 -EPI equation Stage 1 Stage 2 Stages 3-5 S55
25 Access, follow-up & intervention 88.2 Gender Race/ethnicity s.44 participants with a physician Percent with a physician (2 29), N= 119,13 All Male Female White Black Other Hisp % completing follow-up form s.45 follow-up response rate (%) (2 29) Reasons for seeing a physician (%) BP Glucose Urine egfr Hgb Cholesterol Other s.46 Reasons for seeing a physician in participants who return their follow-up forms (2 29), N= 3,216 S56
KEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64
211 Summary Figures S4 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated
More informationKEEP 2009 Summary Figures
S4 29 Summary Figures American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 21:pp S4-S57 S41 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving
More informationKEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.
28 S u m m a r y F i g u r e s American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 29:pp S32 S44. S32 Definitions S33 Data Analyses Diabetes Self-reported diabetes, self reported diabetic retinopathy,
More informationH e alth his to r y. Chapter 3 Health history. s29
3 H e alth his to r y My mama died from undetected kidney disease in Oct. 22. It was only after 2 years of being treated for high blood pressure, a blood test [was done] to check on her kidneys. She went
More informationA n aly tical m e t h o d s
a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationKEEP 2.0 Annual Data Report Chapter Five
KEEP 2. Annual Data Report Chapter Five Figure 5.1 percent distribution of KEEP participants with elevated serum creatinine levels, overall & by age 16 Percent of participants 12 8 4 All
More informationKidney Early Evaluation Program KEEP. A n n u a l D a t a R e p o r t
Kidney Early Evaluation Program KEEP A n n u a l D a t a R e p o r t The National Kidney Foundation gratefully acknowledges the support of our primary sponsor and our associate sponsors Additional thanks
More informationKEEP 2005 Annual Data Report
KEEP 25 Annual Data Report The National Kidney Foundation gratefully acknowledges the support of our primary sponsor and our associate sponsor Additional thanks to Bayer Diagnostics, Satellite Healthcare,
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationEXECUTIVE SUMMARY S3. ONE Program Introduction S5. TWO Participant Characteristics S16. THREE Obesity & Body Mass Index S28
KEEP EXECUTIVE SUMMARY S3 ONE Program Introduction S5 TWO Participant Characteristics S16 THREE Obesity & Body Mass Index S28 FOUR Major Risk Factors for Chronic Kidney Disease S34 FIVE Chronic Kidney
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More informationpatient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62
introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &
More informationAs evidenced by a recent analysis of National
The Kidney Early Evaluation Program (KEEP): Program Design and Demographic Characteristics of the Population Claudine T. Jurkovitz, MD, MPH, 1 Yang Qiu, MS, 2 Changchun Wang, MS, 2 David T. Gilbertson,
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population In light of the 2017 blood pressure guidelines from the American College of Cardiology/American Heart Association (ACC/AHA), this year we examine hypertension control
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationChapter Two Renal function measures in the adolescent NHANES population
0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you
More informationSupplementary Online Content
Supplementary Online Content Swaminathan S, Sommers BD,Thorsness R, Mehrotra R, Lee Y, Trivedi AN. Association of Medicaid expansion with 1-year mortality among patients with end-stage renal disease. JAMA.
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationAddressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationA New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta
A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function
More informationCreatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationCKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
More informationDiabetes Mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES)
Diabetes Mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004 Adam T. Whaley-Connell, DO, MSPH, 1 James R. Sowers, MD, 1 Samy
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCHRONIC DISEASE PREVALENCE AMONG ADULTS IN OHIO
OHIO MEDICAID ASSESSMENT SURVEY 2012 Taking the pulse of health in Ohio CHRONIC DISEASE PREVALENCE AMONG ADULTS IN OHIO Amy Ferketich, PhD Ling Wang, MPH The Ohio State University College of Public Health
More informationAAll s well that ends well; still the fine s the crown; Whate er the course, the end is the renown. WILLIAM SHAKESPEARE, All s Well That Ends Well
AAll s well that ends well; still the fine s the crown; Whate er the course, the end is the renown. WILLIAM SHAKESPEARE, All s Well That Ends Well mthree TrEATMENT MODALITIES 7 ž 21 ATLAS OF ESRD IN THE
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationSummary of Recommendation Statements Kidney International Supplements (2013) 3, 5 14; doi: /kisup
http://www.kidney-international.org & 2013 DIGO Summary of Recommendation Statements idney International Supplements (2013) 3, 5 14; doi:10.1038/kisup.2012.77 Chapter 1: Definition and classification of
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.
Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not
More informationCKD and risk management : NICE guideline
CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of
More informationAshberyh CHAPTER. John
A knowledge that people live close by is, I think, enough. And even if only first names are ever exchanged The people who own them seem rock-true and marvelously self-suficient. John Ashberyh The Ongoing
More informationChapter Two Incidence & prevalence
Chapter Two Incidence & prevalence Science is the observation of things possible, whether present or past. Prescience is the knowledge of things which may come to pass, though but slowly. LEONARDO da Vinci
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationKEEP Data Report Chapter 1: Introduction
KEEP Data Report 2004 Chapter 1: Introduction National Kidney Foundation KEEP Steering Committee Wendy W. Brown, MD, MPH, FACP, FAHA: Chair Meharry Medical College Vanderbilt University Medical Center
More informationKey Elements in Managing Diabetes
Key Elements in Managing Diabetes Presentor Disclosure No conflicts of interest to disclose Presented by Susan Cotey, RN, CDE Lennon Diabetes Center Stephanie Tubbs Jones Health Center Cleveland Clinic
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More information2011 Dialysis Facility Report
Purpose of the Report 2011 Dialysis Facility Report Enclosed is the 2011 Dialysis Facility Report (DFR) for your facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More information2011 Dialysis Facility Report SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE Dialysis Facility Report SAMPLE
Purpose of the Report Enclosed is the (DFR) for your facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR includes data specific to CCN(s): 999999 These data could
More informationChronic Kidney Disease: Optimal and Coordinated Management
Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
Study Summary DAILY ORAL SODIUM BICARBONATE PRESERVES GLOMERULAR FILTRATION RATE BY SLOWING ITS DECLINE IN EARLY HYPERTENSIVE NEPHROPATHY This was a 5-year, single-center, prospective, randomized, placebo-controlled,
More informationSession 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives
Session 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives 1. Understand the impact of chronic kidney disease (CKD) as a common condition of the adult US population.
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationClinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria
Clinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director,
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationCirrhosis and Liver Cancer Mortality in the United States : An Observational Study Supplementary Material
Cirrhosis and Liver Cancer Mortality in the United States 1999-2016: An Observational Study Supplementary Material Elliot B. Tapper MD (1,2) and Neehar D Parikh MD MS (1,2) 1. Division of Gastroenterology
More informationClassification of CKD by Diagnosis
Classification of CKD by Diagnosis Diabetic Kidney Disease Glomerular diseases (autoimmune diseases, systemic infections, drugs, neoplasia) Vascular diseases (renal artery disease, hypertension, microangiopathy)
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationPrevalence of Self-Reported Obesity Among U.S. Adults by State and Territory. Definitions Obesity: Body Mass Index (BMI) of 30 or higher.
Prevalence of Self-Reported Obesity Among U.S. Adults by State and Territory Definitions Obesity: Body Mass Index (BMI) of 30 or higher. Body Mass Index (BMI): A measure of an adult s weight in relation
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationObesity Trends:
Obesity Trends: 1985-2014 Compiled by the Centers for Disease Control and Prevention Retrieved from http://www.cdc.gov/obesity/data/prevalencemaps.html Organized into two groupings due to methodological
More informationManagement of Early Kidney Disease: What to do Before Referring to the Nephrologist
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing
More informationCHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER. The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR
CHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR OUTLINE: A journey through CKD Screening for CKD: The why,
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationLucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*
Cea Soriano et al. Cardiovascular Diabetology (2015) 14:38 DOI 10.1186/s12933-015-0204-5 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular events and all-cause mortality in
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationTAHFA-South Texas HFMA Fall Symposium. Tuesday, October 17, from 10:45 AM 11:35 AM.
1 TAHFA-South Texas HFMA Fall Symposium Tuesday, October 17, from 10:45 AM 11:35 AM. Dr. Anil T. Mangla, MS., PhD., MPH., FRSPH Director of Public Health and Associate Professor of Biomedical Science 2
More informationINDEX WORDS: Awareness; chronic kidney disease; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI); estimated glomerular filtration rate.
KEEP 2010 Comparison of CKD Awareness in a Screening Population Using the Modification of Diet in Renal Disease (MDRD) Study and CKD Epidemiology Collaboration (CKD-EPI) Equations Manjula Kurella Tamura,
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationDiabetic Kidney Disease in the Primary Care Clinic
Diabetic Kidney Disease in the Primary Care Clinic Jess Wheeler, DO Nephrology 2015 Outline: 1. CKD/DKD is a growing problem 2. Diagnosis of Chronic Kidney Disease (CKD) 3. Diagnosis of Diabetic Kidney
More informationExhibit 1. Change in State Health System Performance by Indicator
Exhibit 1. Change in State Health System Performance by Indicator Indicator (arranged by number of states with improvement within dimension) Access and Affordability 0 Children ages 0 18 uninsured At-risk
More informationMetabolic Syndrome: A Preventable & Treatable Cluster of Conditions
Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions April D. McNeill MD Candidate 2016, Southern Illinois University, School of Medicine GE-NMF Primary Care Leadership Program, July 2013
More informationRationale: Objectives: Indication: Diabetes Mellitus, Type 2 Study Investigators/Centers: 300 physicians in 292 clinics Research Methods: Data Source:
GSK Medicine: N/A Study No.: 112255 Title: A Korean, multi-center, nation-wide, cross-sectional, epidemiology study to identify prevalence of diabetic nephropathy in hypertensive patients with type 2 diabetes
More informationSection 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for
Section 1: 1: Trends 1 Patients in the Diabetes Register 2 Gender of Patients with Diabetes 2 Age of Patients with Diabetes 3 Diabetes Type 3 Duration of Diabetes 4 Weight Control 5 Hemoglobin A1c 6 Blood
More informationyear resident, Department of Medicine, B. J. Medical college, Ahmedabad.
Clinical Study of Type 2 Diabetes Mellitus Patients with or without Cerebrovascular Feature and Its Correlation with Other Comorbidity / Diabetic Complication Vivek Sidhapura 1*, Bipin Amin 2, Amit Potulwar
More informationFULFILLMENT OF K/DOQI GUIDELINES 92 anemia treatment dialysis therapy vascular access
INTRODUCTION ANEMIA TREATMENT hemoglobin levels epo treatment iron treatment FULFILLMENT OF K/DOQI GUIDELINES 2 anemia treatment dialysis therapy vascular access EPO DOSING PATTERNS 4 epo dosing per kg
More informationLab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.
Patient Education Lab Values Explained Common Tests to Help Diagnose Kidney Disease Lab work, urine samples and other tests may be given as you undergo diagnosis and treatment for renal failure. The test
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationWhat should you do next? Presenter Disclosure Information. Learning Objectives. Case: George
2:45 3:45pm Optimizing the Management of Patients with Chronic Kidney Disease SPEAKER Jay B. Wish, MD, FACP Presenter Disclosure Information The following relationships exist related to this presentation:
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationScottish Diabetes Survey
Scottish Diabetes Survey 2008 Scottish Diabetes Survey Monitoring Group Foreword The information presented in this 2008 Scottish Diabetes Survey demonstrates a large body of work carried out by health
More informationCARE PATHWAYS. Allyson Ashley
CARE PATHWAYS Allyson Ashley WHAT IS A CARE PATHWAY? An explicit statement of the goals and key elements of care based on evidence, best practice, and patient s expectations and their characteristics The
More information